We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Pml5.0
Pramlintide Research
Mostly mechanism / observationalLimited safety
30 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most Pramlintide studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 2002–2026 with a typical study size of 80 participants.
Based on 30 studies · 2 meta-analyses · 9 RCTs · 2,757 total participants
Confidence
High
By outcome
Weight management
Mostly mechanism / observational22 studies
Blood sugar & glycemic control
Mostly mechanism / observational19 studies
Safety & adverse effects
Mostly mechanism / observational16 studies
Active research area
19 studies in the last 5 years · Latest meta-analysis: 2017
200220142026
1Systematic Review2026
These suggestions aim to determine whether RAS inhibition enhances the overall efficacy of amylin-based therapies, and whether RAS blockers should be strongly recommended in patients receiving them.
Muskiet MHA, Nardone M, Rensen PCN, Cherney DZI, Cooper ME. · Lancet (London, England) (2026)
Paradoxically, new-generation amylin-based therapies, such as CagriSema, showed substantial blood pressure reductions in phase 3 trials.
These suggestions aim to determine whether RAS inhibition enhances the overall efficacy of amylin-based therapies, and whether RAS blockers should be strongly recommended in patients receiving them.
We discuss the potential and challenges of developing amylin-based treatments for cardiometabolic disease, including milestones in drug development of amylin, and its combination with additional molecules as part of the future landscape of therapies for patients with diabetes or obesity.
Secher A, Lutz TA, Raun K. · Nature metabolism (2026)
Almost 20 years later, pramlintide, a human amylin analogue, emerged as the first amylin-based drug, approved as an adjunct treatment to insulin for type 1 diabetes (T1D) and type 2 diabetes (T2D).
Despite its effects on multiple organ systems, the therapeutic potential of amylin has remained relatively underexplored until recently, when growing interest in amylin has prompted advancement of several amylin-based therapies towards clinical use.
This Review contextualizes the evolving therapeutic potential of amylin, focusing on recent preclinical and clinical data, amylin receptor pharmacology and its broader biological effects.
At present, there are growing concerns around GLP1 receptor agonist-based therapeutics, in particular their association with loss of lean body mass.
Additionally, treatment of patients with overweight or obesity without associated comorbidities is increasingly common.
The widespread pharmacotherapy of otherwise healthy populations with overweight or obesity with the goal of improving future health requires further regulatory and ethical consideration.
In this narrative review, we summarized the current evidence and ongoing studies on the mechanism of action, clinical pharmacology, and applications of amylin and its analogs, pramlintide and cagrilintide, in the field of diabetology, endocrinology, and metabolism disorders, such as obesity.
Eržen S, Tonin G, Jurišić Eržen D, Klen J. · International journal of molecular sciences (2024)
The gut-brain axis plays a critical function in maintaining glucose and energy homeostasis and involves a variety of peptides.
Amylin is a neuroendocrine anorexigenic polypeptide hormone, which is co-secreted with insulin from β-cells of the pancreas in response to food consumption.
Aside from its effect on glucose homeostasis, amylin inhibits homeostatic and hedonic feeding, induces satiety, and decreases body weight.
Addition of pramlintide [60 µg three times daily (TID) or four times daily (QID)] to insulin led to significant reductions in HbA(1c) from baseline to Week 52 of 0.29% (P < 0.011) and 0.34% (P < 0.001), respectively, compared with a 0.04% reduction in placebo group.
Ratner RE, Dickey R, Fineman M, Maggs DG, Shen L, Strobel SA, Weyer C, Kolterman OG. · Diabet Med (2004)
Double-blind, placebo-controlled, parallel-group phase-3 RCT in 651 patients with type 1 diabetes, mealtime pramlintide vs placebo added to insulin for 52 weeks
Placebo-corrected HbA1c reduction ~0.3% sustained to week 52; ~3× the proportion of pramlintide vs placebo patients reached HbA1c <7%
Achieved without increased insulin use, and with a ~0.4 kg weight loss vs a 0.8 kg gain on placebo
Treatment with pramlintide 120 µg BID led to a sustained reduction from baseline in HbA(1c) (-0.68 and -0.62% at weeks 26 and 52, respectively)... accompanied by a mean weight loss (-1.4 kg vs. +0.7 kg with placebo at week 52, P < 0.05) and occurred without an overall increase in the severe hypoglycemia event rate.
Hollander PA, Levy P, Fineman MS, Maggs DG, Shen LZ, Strobel SA, Weyer C, Kolterman OG. · Diabetes Care (2003)
52-week double-blind, placebo-controlled, parallel-group phase-3 RCT in 656 insulin-treated patients with type 2 diabetes
Pramlintide 120 µg BID reduced HbA1c by 0.62% at 52 weeks, significantly more than placebo; ~2× as many patients reached HbA1c <8% (46% vs 28%)
Mean weight loss -1.4 kg vs +0.7 kg gain on placebo at week 52, with no overall rise in severe hypoglycemia
This review summarizes recent advancements and discusses their implications for future therapeutic applications in diabesity management.
Chung CW, Kim J. · Journal of obesity & metabolic syndrome (2026)
Combination therapy with glucagon like peptide-1 receptor agonists has achieved synergistic effects, with weight loss exceeding 15%, positioning amylin analogs as a promising approach for treatment of diabesity-the co-existence of diabetes and obesity.
Clinically, the synthetic analog pramlintide has been shown to modestly improve glycemic control and induce weight loss in patients with diabetes.
More recently, cagrilintide, a long-acting analog, has produced substantial weight reduction in individuals with obesity.
Evidence is emerging that long-acting AMYR agonists may show potential therapeutic benefits in treatment of patients with fatty liver disease, diabetes-associated kidney complications and resistant hypertension.
Bailey CJ, Flatt PR, Conlon JM. · Peptides (2026)
Several recently developed long-acting amylin analogues have shown strong efficacy as monotherapy in clinical trials: these include eloralintide, petrelintide, Met-233 and AZD6234.
Other analogues with marked efficacy in preclinical studies, including non-peptide AMYR agonists are under development.
Gastrointestinal side effects, especially nausea, similar to those reported for GLP-1R agonists are commonplace during initiation and up-titration of amylin analogues but mostly resolve during continued use.
Taken together, AMYRAs represent a potential category of therapeutics with promising disease-modifying effects that goes beyond weight loss, providing fresh perspectives for precision obesity management by 2030.
Rejili M, Hussain MS, Khan Y, Haouala F, Ganesan S, Sahoo S, Pal A, Arora V. · Vascular pharmacology (2026)
The agents show enhanced pharmacokinetics, synergy with GLP-1 receptor agonist, and favorable impact on weight regulation and metabolic plasticity.
Genetic CALCR and RAMP mutations, new delivery approaches, and dual therapy by digital health technologies and bariatric surgery are also discussed in this review.
Of particular interest, amylin-derived medications can have advantages over weight loss but definite disease-modifying action remains to be determined.
Odabassian M, Tsoukas MA, Cohen E, Pasqua MR, Rutkowski J, Haidar A. · Journal of diabetes science and technology (2025)
Methods We conducted a pilot, randomized, controlled study to eliminate carbohydrate counting in adults (n = 12, 7 females, age 39.5 [15.1], HbA1c 7.4% [0.6]) using an automated insulin and pramlintide fully closed-loop system.
None of the differences were statistically significant.
Times spent below 3.9 and 3.0 mmol/L were numerically higher with the fully closed-loop aspart and pramlintide systems than the control arm.
Efficacy trials of weekly GLP-1RA and its potential cardio-renal benefits in T1D are much needed.
Saeed ZI, Ambalavanan J, Rayan MN, Patadia P, Shah VN. · Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists (2025)
Results Data shows that GLP-1RAs and SGLTi have demonstrated the greatest efficacy in reducing HbA1c up to 0.7% and 0.5%, respectively, compared to placebo.
GLP-1RAs reduced TDD of insulin by up to 18.5% and weight up to 9.3% (8.3 kg).
SGLTi reduced insulin TDD by up to 15.3% and weight 5.3% (4.3 kg).
Further development of amylin-based therapies or delivery systems is crucial to fully unlock the therapeutic potential of this intriguing hormone.Graphical abstract available for this article.
Volčanšek Š, Koceva A, Jensterle M, Janež A, Muzurović E. · Diabetes therapy : research, treatment and education of diabetes and related disorders (2025)
The novel synergistically acting glucagon-like peptide-1 (GLP-1) receptor agonist combined with the amylin agonist, CagriSema, shows promising results in both glucose regulation and weight management.
As such, amylin agonists (combined with other members of the incretin class) could represent the elusive drug candidate to address the multi-hormonal dysregulations of diabetes subtypes and qualify as a precision medicine approach that surpasses the long overdue division into T1DM and T2DM.
Further development of amylin-based therapies or delivery systems is crucial to fully unlock the therapeutic potential of this intriguing hormone.Graphical abstract available for this article.
In addition, amylin receptor activators may have an adverse effect profile more favorable than that of GLP-1 receptor activators, which could be a potential benefit of amylin receptor activators.
Lee S. · Current drug targets (2025)
Potential issues along with peptide drug development were described, including lipidation to achieve a long-acting property.
The combination of an amylin analog and other anti-obesity peptide drugs has demonstrated higher clinical efficacy in reducing body weight than monotherapy.
The combination therapy is likely to be the first drug therapy where an amylin analog is used for obesity treatment.
However, considering the current issues of high cost, side effects, limited efficacy, and their off-label status, these agents in people with T1D are not widely used in routine clinical care at present.
Apostolopoulou M, Lambadiari V, Roden M, Dimitriadis GD. · Endocrine reviews (2025)
Insulin resistance should therefore be considered a treatment target in T1D.
Aside from lifestyle modifications, continuous subcutaneous insulin infusion can ameliorate insulin resistance and hyperinsulinemia, thereby improving glucose toxicity compared with multiple injection insulin treatment.
Among other concepts, metformin, pioglitazone, incretin-based drugs such as GLP-1 receptor agonists, sodium-glucose cotransporter inhibitors, and pramlintide can improve insulin resistance, either directly or indirectly.
The most exciting future research venue could be the development of their combinations with other weight-lowering drugs, especially dual and triple incretin-based co-agonists, thus potentially providing massive weight-loss effects.
Panou T, Gouveri E, Popovic DS, Papanas N. · Expert review of clinical pharmacology (2024)
Clinical trials confirmed a weight loss exceeding 3% in the study period without major untoward effects, which was maintained beyond the follow-up period.
Cagrilintide has achieved adequate weight loss, reaching even more than 10% of the total weight in early clinical trials.
However, adverse gastrointestinal effects, particularly nausea, were more frequent compared with pramlintide.
Cohen E, Tsoukas MA, Legault L, Vallis M, Von Oettingen JE, Palisaitis E, Odabassian M, Yale JF, Garfield N, Gouchie-Provencher N, Rutkowski J, Jafar A, Ghanbari M, Haidar A. · The Lancet. Digital health (2024)
Non-inferiority of the insulin-and-pramlintide system with simple meal announcements relative to the insulin-and-placebo system with carbohydrate counting was reached (difference -5% [95% CI -9·0 to -0·7], non-inferiority p<0·0001).
No statistically significant difference was found in the mean Emotional Burden score between the insulin-and-pramlintide system with simple meal announcements and the insulin-and-placebo system with carbohydrate counting (difference 0·01 [SD 0·82], p=0·93).
Therefore, more research is needed to individualize therapeutic plans and monitor these patients.
Rudzki G, Knop-Chodyła K, Piasecka Z, Kochanowska-Mazurek A, Głaz A, Wesołek-Bielaska E, Woźniak M. · Pharmaceuticals (Basel, Switzerland) (2024)
The prevalence of PTDM, depending on the source, can range from 4 to 30% in transplant patients.
Patient therapy should not only include standard management such as lifestyle modification, insulin therapy or pharmacotherapy based on well-known oral and injection drugs.
New opportunities are offered by hypoglycemic drugs still in clinical trials, including glucokinase activators, such as dorzagliatin, ADV-1002401, LY2608204, TMG-123, imeglimine, amycretin and pramlintide.
Mealtime pramlintide treatment as an adjunct to insulin improved long-term glycemic control without inducing weight gain or increasing the overall risk of severe hypoglycemia in patients with type 1 diabetes.
Whitehouse F, Kruger DF, Fineman M, Shen L, Ruggles JA, Maggs DG, Weyer C, Kolterman OG. · Diabetes Care (2002)
52-week double-blind, placebo-controlled RCT in 480 patients with type 1 diabetes, 30 µg pramlintide QID vs placebo added to insulin, plus a 1-year open-label extension
HbA1c fell 0.67% from baseline to week 13, significantly more than placebo (0.16%; P<0.0001); a placebo-corrected difference was sustained through week 52
Glycemic benefit was associated with weight loss rather than weight gain and no increase in the overall severe-hypoglycemia event rate
Reductions in A1C (-0.70 ± 0.11% vs. -0.36 ± 0.08%; P < 0.05) and PPG increments... were greater in pramlintide- versus placebo-treated patients... Glycemic improvements were accompanied by progressive weight loss with pramlintide and weight gain with placebo (-1.6 ± 0.3 kg vs. +0.7 ± 0.3 kg; P < 0.0001).
Riddle M, Frias J, Zhang B, Maier H, Brown C, Lutz K, Kolterman O. · Diabetes Care (2007)
16-week double-blind, placebo-controlled RCT in 212 patients with type 2 diabetes on insulin glargine ± oral agents
More pramlintide than placebo patients reached a composite control endpoint (25% vs 7%; P<0.001)
Greater HbA1c reduction (-0.70% vs -0.36%) and lower postprandial glucose increments
In patients taking basal insulin and OADs, premeal fixed-dose pramlintide improved glycemic control as effectively as titrated RAIAs. The pramlintide regimen sometimes caused nausea but no weight gain and less hypoglycemia.
Riddle M, Pencek R, Charenkavanich S, Lutz K, Wilhelm K, Porter L. · Diabetes Care (2009)
24-week open-label RCT in 113 patients with type 2 diabetes, mealtime pramlintide 120 µg vs a titrated rapid-acting insulin analog added to basal insulin
More pramlintide patients reached A1C ≤7.0% without weight gain or severe hypoglycemia (30% vs 11%; P=0.018); similar A1C reductions overall
Rapid-acting insulin caused weight gain (+4.7 kg) while pramlintide did not (+0.0 kg; P<0.0001)